(NasdaqGM:RYTM), — Second quarter 2025 net product revenue from global sales of IMCIVREE(R) (setmelanotide) of $48.5 million — — U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 — — Bivamelagon Phase 2 trial met primary endpoint with statistically significant, clinically meaningful […]
(NASDAQ:AXGN), ALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter Financial Results Second quarter revenue
(NASDAQ:LGIH), THE WOODLANDS, Texas, Aug. 05, 2025 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the second quarter and the six months ended June 30, 2025. “We delivered solid results in the second quarter including profitability metrics at the high end of our prior guidance range,” said Eric Lipar, Chairman
(NasdaqGM:VERA), On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; potential commercial launch in 2026 Announced positive primary endpoint results from the ongoing ORIGIN Phase 3 trial Initiated the PIONEER trial to investigate atacicept in a broader IgAN patient cohort and multiple autoimmune glomerular
(NasdaqGM:OCUL), Outstanding patient retention and clinical execution in complementary AXPAXLI(TM) SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to incorporate single long-term extension study for both SOL trials Ocular to host Investor Day on Tuesday,
(NasdaqGM:SHLS), – Quarterly Revenue of $110.8 million, an increase of 11.7% year over year – – Gross Margin of 37.2% – – Operating Profit of $16.0 million – – Adjusted EBITDA1 of $24.5 million – – Backlog and Awarded Orders at Record Level of $671.3 million – – Provides Third Quarter and Increases Full Year
(NYSE MKT:SACH), – Closed Private Placement of New $100 Million Senior Secured Notes – – Company to Host Webcast and Conference Call – BRANFORD, Conn., Aug. 05, 2025 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) (the “Company”), a real estate lender specializing in originating, underwriting, funding, servicing, and managing a portfolio of loans
(NasdaqGM:SYM), Innovative Design Provides Ultra-High Density for Increased Storage Capacity and/or Reduced Footprint Denser Storage Enables Shorter and Faster Bot Trips per Case Delivery Pre-Assembled Components Deliver Faster Implementation in Customer Sites, Accelerating Time to Value WILMINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) — Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for
(NasdaqGM:CCLD),(NasdaqGM:CCLDP),(NasdaqGM:CCLDO), Delivers first quarter of positive GAAP EPS in Company's history since going public, announces initial results from AI Initiative SOMERSET, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) — CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in healthcare technology and generative AI solutions, today announced strong financial results for the quarter ended
(NASDAQ:BOLD), BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 million in cash supports operations into the first half of 2028, throughexpected proof-of-concept clinical readouts for both programs SAN DIEGO, Aug.